FABP5 and neoplasm: More importantly, given that the immunosuppressive phenotype of TAMs is a key bottleneck affecting the efficacy of current immunotherapies (such as immune checkpoint inhibitors), targeting FABP5 or its mediated lipid metabolism pathways may reverse the pro-tumor function of TAMs, transforming “cold” tumors into “hot” tumors, thereby enhancing the sensitivity and efficacy of immunotherapy.